Literature DB >> 7079745

Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer.

L Tamarkin, D Danforth, A Lichter, E DeMoss, M Cohen, B Chabner, M Lippman.   

Abstract

Plasma melatonin concentrations were determined over a period of 24 hours in 20 women with clinical stage I or II breast cancer. In ten of the patients, whose tumors were estrogen receptor positive, the nocturnal increase in plasma melatonin was much lower than that observed in eight control subjects. Women with the lowest peak concentration of melatonin had tumors with the highest concentrations of estrogen receptors. A significant correlation was found between the peak plasma melatonin concentration and the tumor estrogen receptor concentration in 19 of the patients. These data suggest that low nocturnal melatonin concentrations may indicate the presence of estrogen receptor positive breast cancer and could conceivably have etiologic significance.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7079745     DOI: 10.1126/science.7079745

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  31 in total

1.  Evaluation of melatonin and AFMK levels in women with breast cancer.

Authors:  Tialfi Bergamin de Castro; Newton Antônio Bordin-Junior; Eduardo Alves de Almeida; Debora Aparecida Pires de Campos Zuccari
Journal:  Endocrine       Date:  2018-05-24       Impact factor: 3.633

2.  Melatonin increases the survival time of animals with untreated mammary tumours: neuroendocrine stabilization.

Authors:  M C Saez; C Barriga; J J Garcia; A B Rodriguez; J Masot; E Duran; E Ortega
Journal:  Mol Cell Biochem       Date:  2005-10       Impact factor: 3.396

3.  Associations among salivary cortisol, melatonin, catecholamines, sleep quality and stress in women with breast cancer and healthy controls.

Authors:  Linda E Carlson; Tavis S Campbell; Sheila N Garland; Paul Grossman
Journal:  J Behav Med       Date:  2007-01-24

4.  Estimation of time of death by quantification of melatonin in corpses.

Authors:  H Mikami; K Terazawa; T Takatori; S Tokudome; T Tsukamoto; K Haga
Journal:  Int J Legal Med       Date:  1994       Impact factor: 2.686

Review 5.  Reported biological consequences related to the suppression of melatonin by electric and magnetic field exposure.

Authors:  R J Reiter
Journal:  Integr Physiol Behav Sci       Date:  1995 Sep-Dec

Review 6.  Melatonin in Edible and Non-Edible Plants.

Authors:  Ufuk Koca Çalişkan; Ceylan Aka; Emrah Bor
Journal:  Turk J Pharm Sci       Date:  2017-04-15

7.  Urinary 6-Sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: the ORDET cohort.

Authors:  Eva S Schernhammer; Franco Berrino; Vittorio Krogh; Giorgio Secreto; Andrea Micheli; Elisabetta Venturelli; Sara Grioni; Christopher T Sempos; Adalberto Cavalleri; Holger J Schünemann; Sabrina Strano; Paola Muti
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-03-03       Impact factor: 4.254

Review 8.  Circulating melatonin and the risk of breast and endometrial cancer in women.

Authors:  Akila N Viswanathan; Eva S Schernhammer
Journal:  Cancer Lett       Date:  2008-12-12       Impact factor: 8.679

9.  Urinary excretion of melatonin and association with breast cancer: meta-analysis and review of the literature.

Authors:  Michelle Basler; Alexander Jetter; Daniel Fink; Burkhardt Seifert; Gerd A Kullak-Ublick; Andreas Trojan
Journal:  Breast Care (Basel)       Date:  2014-07       Impact factor: 2.860

Review 10.  Melatonin, an ubiquitous metabolic regulator: functions, mechanisms and effects on circadian disruption and degenerative diseases.

Authors:  Andreea Iulia Socaciu; Răzvan Ionuţ; Mihai Adrian Socaciu; Andreea Petra Ungur; Maria Bârsan; Angelica Chiorean; Carmen Socaciu; Armand Gabriel Râjnoveanu
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.